• About Us
  • Contact Us
  • Cookie policy (EU)
  • Home
  • Privacy Policy
  • Video
  • Write for us
Today Headline
  • HOME
  • NEWS
    • POLITICS
    • News for today
    • Borisov news
  • FINANCE
    • Business
    • Insurance
  • Video
  • TECHNOLOGY
  • ENTERPRISE
  • LIFESTYLE
    • TRAVEL
    • HEALTH
    • ENTERTAINMENT
  • AUTOMOTIVE
  • SPORTS
  • Travel and Tourism
  • HOME
  • NEWS
    • POLITICS
    • News for today
    • Borisov news
  • FINANCE
    • Business
    • Insurance
  • Video
  • TECHNOLOGY
  • ENTERPRISE
  • LIFESTYLE
    • TRAVEL
    • HEALTH
    • ENTERTAINMENT
  • AUTOMOTIVE
  • SPORTS
  • Travel and Tourism
No Result
View All Result
TodayHeadline
No Result
View All Result

Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women

February 4, 2022
in Health
0
Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter


breast cancer
Credit: Unsplash/CC0 Public Domain

A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with estrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of breast cancer recurrence. The results have been published today in The Lancet Oncology.

For women with hormone-sensitive, operable breast cancer, giving tamoxifen treatment after surgery reduces the risk of dying from breast cancer within 15 years by about one third. Aromatase inhibitors, drugs which block estrogen production, are even more effective than tamoxifen in postmenopausal women, reducing this risk by a further 30%.

For premenopausal women, however, aromatase inhibitors are ineffective, since the ovaries respond by increasing estrogen production. However, this problem may be overcome by using treatments that suppress ovarian function, such as drug therapies or surgery. But until now, it was unclear whether aromatase inhibitors or tamoxifen were the most effective treatment for premenopausal women in reducing breast cancer recurrence.

Researchers from the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), based at Oxford Population Health (University of Oxford) and primarily funded by Cancer Research UK, combined all the available evidence to answer this question, since data from individual trials had been inconclusive. They combined data from four large-scale randomized controlled trials, which involved a total of over 7,000 women with early stage breast cancer, from countries across the world.

Each woman had received an ovarian suppressing treatment. In addition, they were randomly allocated to take an aromatase inhibitor or tamoxifen for three or five years. Over a median follow-up period of eight years, the researchers looked for differences between the two groups in breast cancer recurrence, and deaths from breast cancer or any cause.

Key results:

  • Of the total study population, 888 (12.6%) of the women had a breast cancer recurrence. 418 deaths occurred, of which 54 were from causes unrelated to breast cancer.

In women receiving ovarian suppression therapy:

  • Breast cancer recurrence was significantly reduced in the group who had received aromatase inhibitors instead of tamoxifen. Overall, the risk was reduced by an average of a fifth (21%).
  • The main benefit was seen in the first five years, when the treatments differed, where the risk of recurrence was a third (32%) lower in the aromatase inhibitor group. The absolute reduction in the risk of recurrence was 3.2%: 6.9% in the aromatase inhibitor group versus 10.1% in the tamoxifen group.
  • There was no further benefit, or loss of benefit, between five to ten years.
  • Aromatase inhibitors were just as effective in women aged under 35, who have a higher risk of recurrence than older women.
  • There was no apparent difference in the number of deaths from breast cancer or any cause; however survival benefits from aromatase inhibitors may become apparent after a longer period of follow-up.

Known side effects of aromatase inhibitors include an increased risk of osteoporosis, which can cause bone fractures. In the analysis, a slightly higher proportion of women in the aromatase inhibitor group had a bone fracture over the follow-up period, compared with the tamoxifen group: 6.4% vs 5.1%. However, the frequency of bone fractures was low overall, and this can be mitigated through treatment with drugs that help to strengthen bones (bisphosphonates).

Tamoxifen can increase the risk of endometrial abnormalities, including uterine polyps and endometrial cancers. In this analysis, the five-year incidence of endometrial cancer was higher in the tamoxifen group (0.3%) compared with the aromatase inhibitor group (0.2%), but still rare overall.

Lead author, Rosie Bradley from Oxford Population Health says that their “aim was to find out whether premenopausal women treated with ovarian suppression could benefit more from aromatase inhibitors than tamoxifen, and these findings conclusively show this is the case for preventing breast cancer recurrence.”

“However, we need to follow patients for longer to find out whether breast cancer deaths are also reduced. Effects on quality of life need to be considered as well, and it is important that clinicians discuss with patients the potential benefits and risks for each treatment approach.”

Caroline Geraghty, specialist cancer information nurse at Cancer Research UK, says that “this finding has the potential to make a difference in the lives of thousands of women. Most breast cancers are hormone sensitive and treated with hormone therapy. Though there is potential for some side effects, aromatase inhibitors could increase the chance of these women remaining disease free—allowing them to return to normal life.”

“Breast cancer recurrence is especially problematic in younger women, so it’s great news to see that the use of aromatase inhibitors is just as effective in women under the age of 35. We look forward to seeing the results of longer-term follow ups to see if aromatase inhibitors save lives.”


No increased risk of fatal CV events for breast cancer patients on newer hormone therapy


More information:
The Lancet Oncology (2022). www.thelancet.com/journals/lan … (21)00758-0/fulltext

Provided by
Cancer Research UK

Citation:
Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women (2022, February 3)
retrieved 3 February 2022
from https://medicalxpress.com/news/2022-02-aromatase-inhibitors-tamoxifen-breast-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Tags: AromataseBreastcancerinhibitorsrecurrenceReducingrisktamoxifenwomen
Previous Post

Sudoku 5,531 hard

Next Post

A mathematical model may help explain how blood circulates in the brain

Related Posts

Audio: Health Secretary Xavier Becerra declares monkeypox a public health emergency
Health

Audio: Health Secretary Xavier Becerra declares monkeypox a public health emergency

Audio: Health Secretary Xavier Becerra...

Read more
Detox
Health

Latest Study on Detox, Weight Loss and Toxin Elimination: What the Research Says

Every day, we are exposed...

Read more
Two-minute walk after meal helps fight diabetes as helps muscles soak up fuel from food, experts say
Health

Two-minute walk after meal helps fight diabetes as helps muscles soak up fuel from food, experts say

Two-minute walk after a meal...

Read more
Reuters reveals COVID and bust: China’s private health system hurt by tough coronavirus controls
Health

Reuters reveals COVID and bust: China’s private health system hurt by tough coronavirus controls

Health06 July 2022, 7:20 pm....

Read more
What to Look for When Choosing One
Health

Are You Getting Enough Vitamin D?

Vitamin D is well-known for being...

Read more
Load More
Next Post
Mapping the developing brain – ScienceBlog.com

A mathematical model may help explain how blood circulates in the brain

  • Trending
  • Comments
  • Latest
Epic Systems campus, a fantasyland of gardens and architecture, Part 1

Epic Systems campus, a fantasyland of gardens and architecture, Part 1

Redfall is making a 30 minute-long appearance at QuakeCon

Redfall is making a 30 minute-long appearance at QuakeCon

Green-roof prairie and fantasy gardens at Epic Systems, Part 2

Green-roof prairie and fantasy gardens at Epic Systems, Part 2

Six times actors really romped in sex scenes that make 365 DNI look tame

Six times actors really romped in sex scenes that make 365 DNI look tame

She trains formerly incarcerated people to work with plants

She trains formerly incarcerated people to work with plants

Martin Lewis calls on ‘zombie government’ to wake up

Martin Lewis calls on ‘zombie government’ to wake up

Porsche and Piech families seek tighter control of VW

Porsche and Piech families seek tighter control of VW

BMW i5

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

She trains formerly incarcerated people to work with plants

She trains formerly incarcerated people to work with plants

Martin Lewis calls on ‘zombie government’ to wake up

Martin Lewis calls on ‘zombie government’ to wake up

She trains formerly incarcerated people to work with plants

She trains formerly incarcerated people to work with plants

Martin Lewis calls on ‘zombie government’ to wake up

Martin Lewis calls on ‘zombie government’ to wake up

Porsche and Piech families seek tighter control of VW

Porsche and Piech families seek tighter control of VW

  • Real Estate
  • Education
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

No Result
View All Result
  • Real Estate
  • Education
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist